| Factors affecting hematologic recovery and infection in high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk solid tumor |
|
Jung Hyun Lee, Bo Lyun Lee, Soo Hyun Lee, Keon Hee Yoo, Ki Woong Sung, Hye Lim Jung, Eun Joo Cho, Hong Hoe Koo |
|
Department of Pediatrics, Sungkyunkwan University School of Medicine, Seoul, Korea |
| 소아 고형종양의 고용량 화학요법 후 자가 조혈모세포이식에서 혈액학적 회복과 감염에 영향을 주는 요인 |
|
이정현, 이보련, 이수현, 유건희, 성기웅, 정혜림, 조은주, 구홍회 |
|
성균관대학교 의과대학 소아과학교실 |
Correspondence:
Ki Woong Sung, Email: kwsped@smc.samsung.co.kr
|
|
|
|
|
| Abstract |
Purpose
: The purpose of this study was to evaluate factors affecting hematologic recovery and infection in high-dose chemotherapy(HDCT) and autologous stem cell transplantation(ASCT) in patients with high-risk solid tumor.
Methods
: From January 2004 to December 2005, 72 HDCTs and ASCTs were applied to children with high-risk solid tumor at Samsung Medical Center. Medical records of these 72 HDCTs and ASCTs were retrospectively analyzed.
Results
: The single most powerful predictor of neutrophil and platelet recovery was the number of transplanted CD34＋ cells. The duration of high fever was significantly longer in young patients, in patients treated with total body irradiation and/or thiotepa, and in patients transplanted with lower CD34＋ cell dose(<2×106/kg). However, the difference in the duration of high fever according to the number of CD34＋ cells was not clinically significant.
Conclusion
: Findings in this study suggest that HDCT and ASCT with low CD34＋ cell dose is clinically feasible despite delayed hematologic recovery, especially at a dose >1×106/kg per transplantation. Therefore, it is important not to defer the appropriate time for HDCT for an additional collection of hematopoietic stem cells if the number of collected CD34＋ cells is >1×106/kg per transplantation. |
| Key Words:
High-dose chemotherapy , Autologous hematopoietic stem cell transplantation , Pediatric solid tumor |
|
PDF Links
Download Citation
